Merck & Co. (MRK)
(Delayed Data from NYSE)
$113.09 USD
-1.64 (-1.43%)
Updated Sep 26, 2024 04:00 PM ET
Pre-Market: $113.37 +0.28 (0.25%) 9:26 AM ET
4-Sell of 5 4
C Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$113.09 USD
-1.64 (-1.43%)
Updated Sep 26, 2024 04:00 PM ET
Pre-Market: $113.37 +0.28 (0.25%) 9:26 AM ET
4-Sell of 5 4
C Value C Growth B Momentum B VGM
Zacks News
Top Analyst Reports: Amazon, Merck, PepsiCo & More
by Kalyan Nandy
Today's Research Daily features updated research reports on 16 major stocks, including Amazon (AMZN), Merck (MRK) and PepsiCo (PEP).
AstraZeneca's Lupus Drug Meets Primary Endpoint in Study
by Zacks Equity Research
AstraZeneca's (AZN) second phase III study evaluating anifrolumab in adult patients with moderate-to-severe systemic lupus erythematosus meets the primary endpoint.
Esperion's Bempedoic Acid Succeeds in Phase II Diabetes Study
by Zacks Equity Research
A combination regimen of Esperion (ESPR) and Merck's Zetia significantly improves bad cholesterol (LDL-C) levels in patients with both hypercholesterolemia and type II diabetes.
AbbVie Ends Rova-T Program as 3rd Lung Cancer Study Fails
by Zacks Equity Research
IDMC recommends termination of AbbVie's (ABBV) late-stage study on its small cell lung cancer candidate, Rova-T. AbbVie discontinues development.
Why Is Merck (MRK) Up 4.2% Since Last Earnings Report?
by Zacks Equity Research
Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Merck (MRK) is a Top Dividend Stock for Your Portfolio
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Forget Pfizer, Add These Big Drugmakers to Your Portfolio
by Kinjel Shah
Buy these three large drug companies instead of Pfizer (PFE) as the stock is down this year.
Bristol-Myers' Empliciti Gets EMA Nod for Label Expansion
by Zacks Equity Research
Bristol-Myers' (BMY) multiple myeloma drug, Empliciti gets approval in Europe in combination with Celgene's Pomalyst in third or later-line settings.
Here's Why Merck (MRK) is Outperforming Its Industry Of Late
by Zacks Equity Research
Merck's shares are up 11.9% this year so far on strong performance and positive regulatory updates related to its PD-1 inhibitor, Keytruda.
Medicines Company's Inclisiran Succeeds in Pivotal Study
by Zacks Equity Research
The Medicines Company's (MDCO) PCSK9 inhibitor, inclisiran, meets primary endpoint of LDL-C reduction in a pivotal study. Shares up.
Bristol-Myers Announces Sale of Celgene's Otezla to Amgen
by Zacks Equity Research
Bristol-Myers (BMY) announces that Celgene will sell psoriasis drug, Otezla, to Amgen in connection with the ongoing regulatory approval process.
Top Ranked Growth Stocks to Buy for August 27th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, August 27th.
Esperion's Drugs in Review Hold Potential, Funds a Concern
by Zacks Equity Research
Esperion's (ESPR) regulatory applications for bempedoic acid monotherapy and combo therapy seeking approval for lowering LDL-C are under review. However, absence of adequate funds may jeopardize launch.
Top Ranked Growth Stocks to Buy for August 26th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, August 26th.
Roche's Tecentriq Gets Japan's Nod for Small Cell Lung Cancer
by Zacks Equity Research
Roche (RHHBY) gets approval for Tecentriq in Japan for extensive-stage SCLC.
AstraZeneca's Kidney Drug Roxadustat Gets Second Nod in China
by Zacks Equity Research
AstraZeneca's (AZN) roxadustat gets a second marketing approval in China for treating anaemia caused by chronic kidney disease in non-dialysis-dependent patients.
Pfizer's Xtandi Label Expansion Filing Gets Priority Review
by Zacks Equity Research
If data from ARCHES study is approved to be included in the label of Pfizer's (PFE) Xtandi, it can treat a broader prostate cancer patient population.
Glaxo Submits First Regulatory Application for Daprodustat
by Zacks Equity Research
Glaxo (GSK) seeks approval for its anemia candidate, daprodustat, in Japan. Moreover, once every two months administration of cabotegravir and rilpivirine shows non-inferiority to once a month administration in HIV patients in a clinical study.
AstraZeneca's Imfinzi Fails in Stage IV Lung Cancer Study
by Zacks Equity Research
AstraZeneca's (AZN) Imfinzi fails to improve overall survival in a study for previously treated stage IV non-small cell lung cancer (NSCLC) patients.
Bayer Sells Animal Health Division to Elanco: Now What?
by Mitchell Moore
On Tuesday, Bayer (BAYRY) announced the sale of its animal-health division to American competitor Elanco (ELAN), for a net price of $7.6 billion. The deal is expected to close in mid-2020 after regulatory approval.
The Zacks Analyst Blog Highlights: Microsoft, Merck, Walmart, Coca-Cola and Visa
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Microsoft, Merck, Walmart, Coca-Cola and Visa
Buy 5 Dow Stocks That Have Surged Despite Market Gyrations
by Nalak Das
Some members of the Dow 30 Index have offered impressive returns in the past three months and still have upside left.
Pharma Stock Roundup: Pipeline/Regulatory Updates From JNJ, LLY, AZN, RHHBY
by Kinjel Shah
FDA approves Roche's (RHHBY) tumor-agnostic medicine, Rozlytrek, J&J's Sirturo for young TB patients.
AstraZeneca Calquence Gets FDA's Breakthrough Status for CLL
by Zacks Equity Research
The Breakthrough Therapy Designation (BTD) to AstraZeneca's (AZN) Calquence is based on positive interim data from two phase III studies.
Roche Receives FDA Nod for Rozlytrek in ROS1-positive NSCLC
by Zacks Equity Research
Roche's (RHHBY) lung cancer portfolio gets a boost with the approval of yet another drug, Rozlytrek, for metastatic NSCLC.